Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Berlin - Delayed Quote EUR

Oxford BioDynamics PLC (LMQ.BE)

Compare
0.0060
-0.0005
(-7.69%)
As of 2:50:05 PM GMT+1. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
510
510
154
341
456
Cost of Revenue
244
244
38
--
622
Gross Profit
266
266
116
341
-166
Operating Expense
10,434
10,434
8,717
7,853
4,785
Operating Income
-10,168
-10,168
-8,601
-7,512
-4,951
Net Non Operating Interest Income Expense
-141
-141
-184
-83
102
Pretax Income
-11,411
-11,411
-7,567
-7,629
-4,946
Tax Provision
-585
-585
-857
-947
-597
Net Income Common Stockholders
-10,826
-10,826
-6,710
-6,682
-4,349
Diluted NI Available to Com Stockholders
-10,826
-10,826
-6,710
-6,682
-4,349
Basic EPS
-0.07
-0.07
-0.07
-0.07
-0.05
Diluted EPS
-0.07
-0.07
-0.07
-0.07
-0.05
Basic Average Shares
147,481.5660
147,481.5660
99,702.2570
92,559.7710
92,558.3170
Diluted Average Shares
147,481.5660
147,481.5660
99,702.2570
92,559.7710
92,558.3170
Total Operating Income as Reported
-10,168
-10,168
-8,601
-7,512
-4,951
Rent Expense Supplemental
--
--
--
--
38
Total Expenses
10,678
10,678
8,755
7,853
5,407
Net Income from Continuing & Discontinued Operation
-10,826
-10,826
-6,710
-6,682
-4,349
Normalized Income
-9,751.0847
-9,751.0847
-7,680.9859
-6,682
-4,349
Interest Income
72
72
11
31
121
Interest Expense
213
213
195
114
19
Net Interest Income
-141
-141
-184
-83
102
EBIT
-11,198
-11,198
-7,372
-7,515
-4,927
EBITDA
-9,841
-9,841
-6,159
-6,427
-4,460
Reconciled Cost of Revenue
244
244
38
--
622
Reconciled Depreciation
1,357
1,357
1,213
1,088
467
Net Income from Continuing Operation Net Minority Interest
-10,826
-10,826
-6,710
-6,682
-4,349
Total Unusual Items Excluding Goodwill
-1,133
-1,133
1,095
--
--
Total Unusual Items
-1,133
-1,133
1,095
--
--
Normalized EBITDA
-8,708
-8,708
-7,254
-6,427
-4,460
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-58.0847
-58.0847
124.0141
--
--
9/30/2020 - 1/19/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INTS Intensity Therapeutics, Inc.
2.3400
+6.36%
 
WXXWY WuXi Biologics (Cayman) Inc.
5.75
+0.93%
 
PTGX Protagonist Therapeutics, Inc.
37.59
+3.44%
 
NNVC NanoViricides, Inc.
1.3200
-1.49%
 
ROIV Roivant Sciences Ltd.
10.74
+3.47%
 
TNXP Tonix Pharmaceuticals Holding Corp.
7.86
-3.91%
 
ENVB Enveric Biosciences, Inc.
2.8000
+32.08%
 
NVAX Novavax, Inc.
8.33
+17.99%